Organon's commercial director and lead for the South Asia region, Anjan Sen, discusses with Scrip the prospects of contraceptive Implanon NXT with its inclusion in India’s historic family planning program. The Merck spin-out is also on course to debut its Jada System this year, opening up new growth avenues as it disentangles and builds out operations in the region.

China's Zai Lab and Everest are still pursuing profitability on the commercialization of in-licensed assets, while BioNova and others have already bowed out of the game.

This week, AliveCor's patent infringement lawsuit against Apple came to an end; industry stakeholders submitted comments to the FTC on the right to repair; Cardinal Health and Percussionaire announced recalls; and the IMDRF announced a March meeting in Washington, DC.

The Phase II LUNA study of ixo-vec showed a reduction in anti-VEGF use and stabilization of visual acuity and anatomic parameters that Adverum – and some analysts – called best in class.